Gastrointestinal tuberculosis following renal transplantation accompanied with septic shock and acute respiratory distress syndrome:A survival case presentation by Cikova, Andrea et al.
  
 University of Groningen
Gastrointestinal tuberculosis following renal transplantation accompanied with septic shock
and acute respiratory distress syndrome
Cikova, Andrea; Vavrincova-Yaghi, Diana; Vavrinec, Peter; Dobisova, Anna; Gebhardtova,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Cikova, A., Vavrincova-Yaghi, D., Vavrinec, P., Dobisova, A., Gebhardtova, A., Flassikova, Z., ... Yaghi, A.
(2017). Gastrointestinal tuberculosis following renal transplantation accompanied with septic shock and
acute respiratory distress syndrome: A survival case presentation. Bmc gastroenterology, 17(1), [131].
https://doi.org/10.1186/s12876-017-0695-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
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Gastrointestinal tuberculosis following renal
transplantation accompanied with septic
shock and acute respiratory distress
syndrome: a survival case presentation
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Zora Flassikova1, Mark A. Seelen3, Robert H. Henning4 and Aktham Yaghi1
Abstract
Background: Post-transplant tuberculosis (PTTB) is a serious opportunistic infection in renal graft recipients with a
30-70 fold higher incidence compared to the general population. PTTB occurs most frequently within the first years
after transplantation, manifesting as pulmonary or disseminated TB. Gastrointestinal TB (GITB) is a rare and potentially
lethal manifestation of PTTB and may show delayed onset in renal transplant recipients due to the use of lower doses
of immunosuppressants. Further, non-specificity of symptoms and the common occurrence of GI disorders in
transplant recipients may delay diagnosis of GITB.
Case presentation: Here we report a rare survival case of isolated GITB in a renal transplant recipient, occurring seven
years after transplantation. The patient’s condition was complicated by severe sepsis with positive blood culture
Staphylococcus haemolyticus, septic shock, multiple organ failure including acute respiratory distress syndrome (ARDS)
and acute renal failure, requiring mechanical ventilation, vasopressor circulatory support and intermittent hemodialysis.
Furthermore, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurred during
hospitalization. Antituberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated
upon Mycobacterium confirmation. Moreover, treatment with voriconazole due to the Aspergillus flavus and
meropenem due to the Pseudomonas aeruginosa was initiated, the former necessitating discontinuation of
rifampicin. After 34 days, the patient was weaned from mechanical ventilation and was discharged to the
pulmonary ward, followed by complete recovery.
Conclusion: This case offers a guideline for the clinical management towards survival of GITB in transplant patients,
complicated by septic shock and multiple organ failure, including acute renal injury and ARDS.
Keywords: Gastrointestinal tuberculosis, Renal transplantation, Multiple organ failure, Acute respiratory distress
syndrome, Septic shock
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Background
Post-transplant tuberculosis (PTTB) is a serious oppor-
tunistic infection in renal graft recipients significantly
increasing mortality and morbidity [1]. The incidence of
PTTB among transplant recipients is 30-70 fold higher
compared to the general population, with a significant
risk of graft loss and a mortality rate up-to 30% [2].
PTTB is usually the result of reactivation of latent tuber-
culosis infection, although primary infection or trans-
mission of Mycobacterium tuberculosis via the renal
graft has been occasionally reported [3]. PTTB occurs
most frequently within the first 2 years after transplant-
ation, with a median interval of 8 months [4]. The
overall prevalence of PTTB is reported to be 0.3-1.7% in
the United States and Western Europe. In developing
countries, PTTB prevalence is much higher, ranging
between 3.1-15.2% due to the higher prevalence of
tuberculosis in those areas [1]. The most common mani-
festation of PTTB in renal transplant patients is pulmon-
ary TB [5]. One third of all cases of PTTB involve
disseminated and extra-pulmonary TB [6]. Amongst the
very rare manifestations of PTTB is gastrointestinal TB
(GITB) [1]. GITB is potentially lethal [7] and because of
its nonspecific symptoms and laboratory findings, diag-
nosis is often challenging [8]. Moreover, limited data are
available regarding the prevalence of GITB among renal
transplant recipients [1]. Further, although uncommon,
extensive TB of the pulmonary parenchyma, as observed
in the course of miliary TB, may cause acute respiratory
distress syndrome (ARDS) [9], which is associated with a
60% in-hospital mortality [10]. Mortality increases to
100% when acute kidney injury ensues [11]. So far, a case
of post-transplant GITB complicated by ARDS has not
been reported.
Here we report a case of isolated GITB in a renal
transplant recipient, occurring seven years after trans-
plantation. Moreover, the patient’s condition was
complicated by severe sepsis with positive blood culture
for Staphylococcus haemolyticus, septic shock and mul-
tiple organ failure including ARDS and acute renal
failure, requiring mechanical ventilation, vasopressor
circulatory support and intermittent hemodialysis. Fur-
thermore, nosocomial infections including invasive as-
pergillosis and Pseudomonas aeruginosa occurred during
hospitalization.
Case presentation
A 53-year-old female renal allograft recipient with a his-
tory of hypertension presented to the intensive care unit
(ICU) with a septic shock and multi-organ failure. In the
past, left nephrectomy had been performed due to
kidney dysfunction. Seven years before admission, she
underwent deceased-donor renal transplantation due to py-
elonephritis of the right kidney. The immunosuppressive
regimen included methylprednisolone, mycophenolate
mofetil (1000 mg-0-1000 mg) and cyclosporine
(25 mg-0-50 mg).
Since 7 months, the patient had been re-admitted re-
peatedly to other hospitals because of recurrent fever,
however without demonstration of an infectious agent.
One month earlier she had been admitted to the hospital
because of dyspnoea and dry cough. Atypical right bron-
chopneumonia was suspected based on computed tom-
ography (CT) of the lungs and treated empirically with
antibiotic therapy including piperacillin/tazobactam,
metronidazole, and fluconazole. Since the patient was
deteriorating, she was admitted to the pulmonary ICU
of our hospital.
Post-surgery (PO) admission day 1
Because of a history of weight loss and the patient start-
ing to complain of abdominal pain at the pulmonary
ICU, and the presence of anemia and intestinal
hemorrhage, an abdominal CT was performed. The CT
revealed ascites, enlarged uterus with wall thickening,
enlarged left ovarium, as well as enlarged mesenteric
and retroperitoneal lymph nodes. Further, the low thor-
acic area showed bilateral pleural effusion and
hydropericardium.
Because of the massive intestinal hemorrhage, surgery
was needed four days after admission to the pulmonary
ICU, during which a right-sided hemicolectomy with
side-to-side ileotransverse anastomosis was performed.
Additionally, left adnexectomy was performed, because
inflammatory tumor lesions were found. As her condi-
tion deteriorated post-operatively, the patient was intu-
bated, analgo-sedated to Glasgow Coma Scale 3 (GCS 3)
and artificially ventilated with inspired FiO2 0.65-1.
Norepinephrine was administered for hypotension.
The patient was transferred to our ICU after 24 h of
mechanical ventilation in the pulmonary ICU, because
of progression of multiple organ failure, including
acute renal failure.
On admission at 9:15 a.m., under norepinephrine ad-
ministration (0.4 μg/kg/min), blood pressure was 110/
50 mmHg, HR was 117/min, temperature 37.2 °C, and the
patient was anuric. Laboratory analyses revealed com-
bined metabolic and respiratory acidosis (pH 7.136, pCO2
7.8 kPa, BE −11 mmol/l, pO2 12.65 kPa, HCO3
16.1 mmol/l, O2 saturation 93.4%, paO2/FiO2 94, arterial
lactate 2.13 mmol/l), and hyperkalemia (6.29 mmol/l),
hyperchloremia (121.7 mmol/l), elevated blood urea and
creatinine (13.11 mmol/l and 179.5 μmol/l, respect-
ively), AST 346.4 U/l and elevated C-reactive protein
(196.2 mg/l) and procalcitonin (2.14 μg/l). Blood ana-
lyses corroborated massive blood loss (Hb 82 g/l, Ht
0.24, RBC 2.77 × 1012/l) and showed WBC 14.2 × 109/l
and PLT 147 × 109/l. After the admission, cannulation
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of left subclavian vein and the left radial artery was
performed. Left thoracic drainage was performed due
to an iatrogenic left anterior pneumothorax, con-
firmed by CT, which also showed extensive diffuse bi-
lateral infiltrates (Fig. 1a, b). At 12 a.m., blood
culture from a blood sample taken upon admission
was found positive for Staphylococcus haemolyticus.
Moreover, Staphyloccocus aureus was cultured from
the abdominal cavity. Subsequently, linezolid was
added to the therapeutical regimen.
Histology tissue specimens obtained from the abdom-
inal cavity revealed granuloma, indicative of tuberculous
enteritis, peritonitis, adnexitis and lymphadenitis.
Ziehl-Neelsen staining revealed an abundance of gram
positive bacterial pathogens type Mycobacterium. A final
diagnose of systemic mycobacteriosis, with superinfec-
tion due to the chronic immunosuppressive therapy was
made. Antimycobacterial therapy was initiated with
rifampicin, isoniazid, ethambutol and pyrazinamide.
Intravenous administration of ciprofloxacin, piperacillin/
tazobactam and linezolid was continued. Following the
advice of the nephrologist, mycophenolate mofetil was
discontinued and immunosuppressive therapy was
continued with hydrocortisone. Later that day, the pa-
tient was turned to the prone position because of severe
ARDS (Fig. 1a, b), for seven hours without improvement
in oxygenation (Fig. 2 – timeline with interventions and
medications).
PO day 2 and further
On day 2 of admission to the ICU, oxygenation im-
proved (paO2/FiO2 185), while norepinephrine was con-
tinued (up to 0.5 μg/kg/min.). As oliguria persisted,
intermittent hemodialysis was indicated (4 h/day). Prior
to dialysis, laboratory analyses showed urea 21 mmol/l,
creatinine 261.9 μmol/l, potassium 6.22 mmol/l and
metabolic acidosis.
Day 3. Intermittent hemodialysis was maintained (4 h/day)
and spontaneous diuresis increased to 760 ml/24 h. Norepin-
ephrine infusion rate was gradually lowered.
Day 4. Final intermittent hemodialysis was indicated
(4 h/day).
Day 5. Norepinephrine was discontinued.
Day 6. Tracheostomy was performed. Mycobacterium
tuberculosis in sputum was confirmed by polymerase
chain reaction (PCR).
Fig. 1 Computer tomography scans at day 1 of admission. CT scan shows acute respiratory distress syndrome (ARDS), diffuse bilateral infiltrates
(black arrows), pneumothorax (red arrow) and chest tube (white arrow) (a), detailed CT scan (b)
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Day 11. Mycophenolate mofetil was re-added to the
immunosuppressive regimen.
Day 15. The analyses of sputum revealed filamentous
fungi without further specification – the clinical
pharmacologist prescribed anidulafungin for yeast super-
infection following sensitivity testing (initial dose
200 mg i.v., then 100 mg i.v. every 24 h).
Day 16. Anidulafungin resistant Aspergillus flavus
was confirmed in sputum, prompting addition of vori-
conazole to the current treatment (initial dose
300 mg i.v. every 12 h, then 200 mg i.v. every 12 h).
The pulmonologist was consulted because of inter-
action between antimycotic agents and rifampicin.
Because of the invasive aspergillosis, rifampicin was
stopped.
Day 21. Because of low voriconazole serum level, the
dose was increased to 400 mg i.v. every 12 h.
Day 23. Due to the Pseudomonas aeruginosa in the
sputum, meropenem i.v. was added to the antimicrobial
regimen.
Day 34. The patient was weaned from mechanical
ventilation and breathed spontaneously through the
tracheostomy tube with O2. The tracheostomy tube was
removed four days later.
Day 42. The patient was discharged to the pulmonary
ward, with the following medication: methylpredniso-
lone, cyclosporine, hydrocortisone, rifampicin, isoniazid
and pyrazinamide.
Discussion and conclusions
This case demonstrates both typical and non-typical fea-
tures associated with GITB in renal transplant patients.
First, reactivation of latent TB infection was only ob-
served 7 years after transplantation, which is unusually
late, as most cases occur in the first 2 years after trans-
plantation [1]. However, several reports show that the
median time of onset of GITB may be longer in renal
transplant recipients, possibly due to the lower doses of
immunosuppressants in those recipients compared to
other transplant recipients [1, 3]. This might have been
also the case of our patient, as her immunosuppressive
regimen consisted of lower doses of mycophenolate mo-
fetil (1000 mg two times daily) compared to e.g. heart or
liver transplant patients (1500 mg two times daily).
Moreover, the dose of cyclosporine was decreased sev-
eral weeks after renal transplantation.
GITB occurs usually due to the reactivation of latent
TB infection because of immunosuppressive therapy, or
(but less commonly) it is transmitted by the allograft it-
self; alternatively, it may result from primary infection
[3]. Immunosuppressive therapy affecting the function of
cell-mediated immunity such as cyclosporine, mycophe-
nolate mofetil and monoclonal and polyclonal antibodies
during the first years after transplantation have been as-
sociated with TB reactivation [3, 12–14]. Our patient’s
immunosuppressive therapy included both cyclosporine
and mycophenolate mofetil, however, other risk factors
Fig. 2 Timeline with essential interventions and medications. tx, transplantation; IS, immunosuppressive regimen; MP, methylprednisolone; MMF,
mycophenolate mofetil; CsA, cyclosporine; P/T, piperacillin/tazobactam; METRO, metronidazole; FLU, fluconazole; LIN, linezolid; CIPRO, ciprofloxacin; RIF,
rifampicin; ISO, isoniazid; ETH, ethambutol; PYR, pyrazinamide; ARDS, acute respiratory distress syndrome; PCR, polymerase chain reaction; VORI,
voriconazole; HC, hydrocortisone; ATB, antituberculosis therapy
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of reactivation (such as pretransplant diabetes, the num-
ber of acute rejections of transplanted graft resulting in
higher dosing of immunosuppression, opportunistic in-
fections, chronic liver diseases and duration of pre-
transplant hemodialysis) were unknown. Interestingly,
the receipt of a graft from a deceased donor rather than
other sources of donors was recently identified as im-
portant risk factor for developing TB in liver or kidney
transplant recipients [15], which is in accordance with
our case.
Although GITB in our patient occurred most likely
due to the latent reactivation, primary infection or trans-
mission via the renal graft cannot be explicitly excluded.
However, no recent TB exposure, or significant travel
history was reported.
On readmission to the hospital, and subsequent ad-
mission to pulmonary ICU, the patient displayed several
symptoms commonly found in GITB, including recur-
rent fever, weight loss, abdominal pain and anemia. The
symptoms of GITB in non-transplant patients constitute
abdominal pain, weight loss - even anorexia, fever,
anemia and bowel habit change [8, 16]. However, in
renal transplant recipients, the most common symptoms
of decreased inflammatory response due to the immuno-
suppressive therapy [1, 8] are GI bleeding accompanied
by fever and abdominal pain [1]. Furthermore, the symp-
toms in renal transplant recipients are also often very
vague and sometimes plain unusual. Moreover, GI disor-
ders in transplant recipients are relatively common, and
are also associated with immunosuppressive therapy or
bacterial, viral or parasitic infection [2, 3]. One of the
main adverse effects of mycophenolate mofetil is GI irri-
tation [17]. Together, these are causing an important
delay in the diagnosis, contributing to the extremely
high mortality of renal transplant recipients with GITB.
Some authors reported that the late manifestation of
GITB in renal transplant recipients is related mainly to
this diagnostic delay because of lack of specific symp-
toms [18]. Therefore, all GI symptoms in renal trans-
plant recipients, although vague, require diagnostic
follow up for GITB, albeit confirming the diagnosis may
be challenging. CT may often reveal inflammation, asci-
tes (our patient) and lymphadenopathy (our patient).
These unspecific features may lead to alternative diagno-
ses (neoplasms, inflammation or nontuberculosis
bacterial or other viral infections or parasites). The
microbiological confirmation is often tricky because of
difficulties in obtaining the suitable tissue, low sensitivity
of microbiological examination and the protracted time
needed for culture [19]. Moreover, in immunosuppressed
patients skin anergy is frequent; resulting in negative
skin tuberculin tests [20] and endoscopic distinction be-
tween GITB and other GI diseases (e.g. Crohn’s disease)
is difficult. In our patient, tissue specimens obtained
from abdominal cavity revealed granulomas with
Mycobacterium. Six days later, Mycobacterium tuber-
culosis was confirmed by PCR in the sputum. How-
ever, CT scan of the lungs revealed no specific
lesions, except for atypical right bronchopneumonia.
Although we advocate that PCR may be the first line
tool in GITB diagnosis, it does not differentiate be-
tween an active and latent infection [21]. GITB can
coexist with pulmonary involvement; however reports
have shown that less than 50% of patients infected
with GITB have radiographic evidence of pulmonary
disease. A case report of Yilmaz et al. demonstrated
renal transplant recipient with GITB, however without
X-ray abnormalities [22]. Swallowing of infected spu-
tum in patients with active pulmonary TB belongs to
the most common mechanism of GITB origin [23].
In addition, massive intestinal bleeding occurred in
line with previous reports showing GI bleeding present
in most renal transplant recipients with GITB [1]. As
mentioned above, GI bleeding is the most common
symptom of posttransplant GITB (in contrast with GITB
in a non-transplant population). This could be again due
to the decreased inflammatory response because of the
immunosuppression; hence the ulcerative disease com-
ponent is predominant rather than obstructive bowel
wall inflammation [1]. Moreover, tissue specimens ob-
tained from the abdominal cavity revealed granuloma,
the indicative of tuberculous enteritis, peritonitis, adnex-
itis and lymphadenitis, which is in line with a previous
report [7]. Except for its very late onset, likely due to the
low doses of immunosuppressive therapy, and further
complications, this case thus represents a typical ex-
ample of reactivation of latent tuberculosis infection,
resulting in GITB with vague abdominal complaints and
intestinal bleeding.
Upon observing Mycobacterium in tissue obtained
from the abdominal cavity, antituberculosis therapy was
initiated, consisting of rifampicin, isoniazid, ethambutol
and pyrazinamide. However, antituberculosis therapy
increases the risk of interactions and toxic hepatitis. Ri-
fampicin is a strong inducer of microsomal enzyme
P450 3A4, which leads to increased metabolism of
calcineurin-inhibitors, rapamycin and steroids [24]. Ri-
fampicin reduces plasma levels of cyclosporine 2-5 fold
and tacrolimus 4-10 fold [1], which increases the risk of
rejection [13]. Moreover, common TB medications may
lead to interactions with other required drugs, as
documented with our case. Therefore, it is strongly rec-
ommended to closely monitor and adjust plasma
concentrations of drugs, particularly those of the
calcineurin-inhibitors, to avoid both toxicity and graft
rejection. Therefore mycophenolate mofetil was discon-
tinued for 11 days due to the septic shock (severe infec-
tion), while cyclosporine dosage was increased from
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25 mg-0-50 mg to 100 mg-0-100 mg. Moreover, our pa-
tient’s condition was complicated with aspergillosis and
Pseudomonas aeruginosa infection. Therefore, voricona-
zole and meropenem was added to the therapeutic
regimen. However, low plasma level of voriconazole was
found in the plasma of our patient, likely because of the
interaction with rifampicin. Thus, the voriconazole doses
also had to be adjusted, while rifampicin was discontin-
ued for one day.
During hospitalization, nosocomial infections includ-
ing anidulafungin resistant Aspergillus flavus and
Pseudomonas aeruginosa occurred. Immunocomprom-
ised patients are more vulnerable for nosocomial infec-
tions, especially early after transplantation. On day 1 PO
mycophenolate mofetil was discontinued, however on
day 11 PO was again re-added to the therapeutic
regimen. Subsequently, both Aspergillus flavus and
Pseudomonas aeruginosa was confirmed from the spu-
tum on day 16 and 23 PO. Aspergillus infection occurs
almost exclusively in immunosuppressed hosts [25], and
is associated with increased morbidity and mortality
among transplant recipients [26]. Pseudomonas aerugi-
nosa, a major nosocomial pathogen, belongs to the
life-threatening complication after abdominal organ
transplantation. The survival rates are significantly lower
for patients with hypotension and on mechanical ventila-
tion, and the predictor of mortality related to Pseudo-
monas bacteremia is the onset of bacteremia in the ICU
[27]. Furthermore, the multiple nosocomial infections
could be related to previous repeated admission to the
hospital or to the prolonged ICU stay (>3 days). In order
to reduce risk of nosocomial infection in immunocom-
promised patients, it is necessary to take preventive
measures, such as thorough decontamination and hand
hygiene, aseptic procedures, or prophylactic antibiotic
therapy. Moreover it is important to reduce the infection
risk from use of catheters, cannulas, or tubes. Transplant
recipients should receive an empirical antibiotic treat-
ment as well as directed therapy adjusted according to
the severity of the infection [28].
Our patient’s condition was furthermore compli-
cated with severe sepsis with Staphylococcus haemo-
lyticus blood culture, septic shock, multiple organ
failure including ARDS and acute renal failure
requiring mechanical ventilation, vasopressor circula-
tory support and intermittent hemodialysis. Reports
of ARDS associated with TB are not scarce; most
studies report ARDS to be caused by pulmonary TB,
which is associated with in-hospital mortality rates
higher than from non-TB causes (e.g. pneumonia)
[10, 29]. ARDS may be very rarely caused by miliary
TB [10]. To our best knowledge however, there is no
case study investigated posttransplant GITB compli-
cated with ARDS.
Although treatable and very rare, GITB is a potentially
lethal complication after solid organ transplantation.
Onset of GITB is most commonly about 2 years after
transplantation, however in renal transplant recipients,
with modest immunosuppressive therapy time to mani-
festation can be longer (our patient). Diagnosis of GITB
is challenging, because symptoms are often vague and
atypical and renal graft recipients often display GI symp-
toms. However, early diagnosis is crucial for successful
treatment. Therefore, both GI symptoms and fever at
any time after transplantation should trigger active diag-
nostic workup for GITB, especially in the absence of an-
other confirmed infection. Furthermore, (GI)TB
treatment in transplant patients poses specific problems
because of interactions between antituberculosis drugs
and immunosuppressive therapy, especially when other
comorbidities such as aspergillosis need to be treated
(our patient). Thus, plasma drug levels need to be
closely monitored. In case septic shock occurs (our
patient), the immunosuppressive therapy may be discon-
tinued. Moreover, GITB could be complicated with mul-
tiple organ failure including ARDS and acute renal
failure, which may necessitate mechanical ventilation,
vasopressor circulatory support and hemodialysis.
Nevertheless, the case currently presented demonstrates
that by implementing the above recommendations, sur-
vival from GITB complicated by septic shock and mul-
tiple organ failure including acute renal injury and
ARDS may be accomplished.
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